Logo - International Journal of Pharmaceutical Compounding

Stability of Atenolol, Clonazepam, Dexamethasone, Diclofenac Sodium, Diltiazem, Enalapril Maleate, Ketoprofen, Lamotrigine, Penicillamine-D, and Thiamine in SyrSpend SF PH4 Oral Suspensions

Author(s):  Polonini HC, Loures S, Lima LC, Ferreira AO, Brandão MA

Issue:  Mar/Apr 2016 - Volume 20, Number 2
View All Articles in Issue

Abstract:  The objective of this study was to evaluate the stability of 10 commonly used active pharmaceutical ingredients compounded in oral suspensions using SyrSpend SF PH4 (atenolol 1.0 and 5.0 mg/mL, clonazepam 0.2 mg/mL, dexamethasone 1.0 mg/mL, diclofenac sodium 5.0 mg/mL, diltiazem 12.0 mg/mL, enalapril maleate 1.0 mg/mL, ketoprofen 20.0 mg/mL, lamotrigine 1.0 mg/mL, penicillamine-D 50.0 mg/mL, thiamine 100 mg/mL) and stored both at controlled refrigerated (2°C to 8°C) and room temperature (20°C to 25°C). Stability was assessed by means of measuring percent recovery at varying time points throughout a 90-day period. The quantification of the active pharmaceutical ingredients was performed by a stability-indicating, high-performance liquid chromatographic method. The beyond-use date of the products was found to be at least 90 days for all suspensions (except atenolol 1 mg/mL, which was stable up to 60 days), both for controlled refrigerated temperature and room temperature. This confirms that SyrSpend SF PH4 is a stable suspending vehicle for compounding with a broad range of different active pharmaceutical ingredients.

Related Keywords: Hudson C. Plolnini, BPharm, PhD, Sharlene Loures, Bbiomed, Luis Claudio Lima, BPharm, Anderson O. Ferriera, Bphar, PhD Candidate, Marcos Antônio F. Brandão, BPharm, PhD, atenolol, clonazepam, dexamethasone, diclofenac sodium, diltiazem, enalapril maleate, ketoprofen, lamotrigine, penicillamine-D, thiamine, oral suspensions, liquid suspending vehicles, liquid dosage forms, stability, storage conditions, beta blocker, beta adrenergic antagonist, benzodiazepine, corticosteroid, nonsteroidal anti-inflammatory drugs, NSAID, non-dihydropyridine calcium channel blocker, angiotensin converting enzyme inhibitor, ACE inhibitor, anticonvulsant agent, mood stabilizer, chelating agents, chelator, immunosuppressant, immunosuppressive agent


Purchase this article for download in electronic PDF format from IJPC at for $35 at:

Search the entire IJPC archive by keyword, topic, or issue at: